State of Tennessee Department of Treasury Sells 27,726 Shares of Moderna, Inc. (NASDAQ:MRNA)

State of Tennessee Department of Treasury lessened its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 22.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 95,690 shares of the company's stock after selling 27,726 shares during the period. State of Tennessee Department of Treasury's holdings in Moderna were worth $3,979,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. FMR LLC grew its stake in shares of Moderna by 7.4% in the fourth quarter. FMR LLC now owns 18,664,634 shares of the company's stock valued at $776,075,000 after buying an additional 1,282,469 shares in the last quarter. Geode Capital Management LLC raised its holdings in Moderna by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company's stock valued at $300,219,000 after acquiring an additional 171,774 shares in the last quarter. Invesco Ltd. grew its stake in Moderna by 24.3% during the fourth quarter. Invesco Ltd. now owns 5,006,462 shares of the company's stock worth $208,169,000 after buying an additional 979,858 shares in the last quarter. Norges Bank bought a new position in shares of Moderna in the 4th quarter valued at $163,833,000. Finally, Charles Schwab Investment Management Inc. grew its position in Moderna by 9.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,344,203 shares of the company's stock valued at $97,472,000 after acquiring an additional 211,426 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. Evercore ISI set a $50.00 target price on shares of Moderna in a report on Friday, February 14th. Morgan Stanley lowered their price objective on shares of Moderna from $39.00 to $32.00 and set an "equal weight" rating for the company in a research note on Wednesday, April 9th. UBS Group decreased their target price on Moderna from $96.00 to $78.00 and set a "buy" rating for the company in a research report on Wednesday, February 19th. The Goldman Sachs Group lowered shares of Moderna from a "buy" rating to a "neutral" rating and decreased their price target for the company from $99.00 to $51.00 in a research note on Wednesday, January 29th. Finally, Bank of America dropped their price target on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research report on Tuesday, February 11th. Four investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Moderna presently has an average rating of "Hold" and a consensus target price of $58.70.

Moderna Trading Up 1.3 %

Shares of MRNA traded up $0.36 during mid-day trading on Tuesday, reaching $27.82. 5,238,914 shares of the stock traded hands, compared to its average volume of 7,348,918. The firm has a fifty day moving average price of $30.03 and a 200 day moving average price of $38.15. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $170.47. The company has a market cap of $10.76 billion, a price-to-earnings ratio of -3.00 and a beta of 2.23.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.